Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after
initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for
maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant
side effect or disease progression appear . The follow-up period is approximately 2 years.